Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. GAZYVARO
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

GAZYVARO

Medicine - Posted on May 04 2018 - Updated on Jun 12 2019
Active substance (DCI)
  • obinutuzumab
history (3)
  • 4/18/18

    GAZYVARO (obinutuzumab)

    GAZYVARO (obinutuzumab)
    CAV :
    54321
    icône flèche
  • Economic analysis
    3/8/17

    GAZYVARO (obinutuzumab), monoclonal antibody

    No clinical benefit demonstrated in combination with bendamustine followed by Gazyvaro maintenance for the treatment of pati...
    CAV :
    54321
    icône flèche
  • Economic analysis
    2/18/15

    GAZYVARO (obinutuzumab), type II humanised anti-CD20 recombinant monoclonal antibody

    Moderate improvement in the treatment of previously untreated chronic lymphocytic leukaemia in patients with comorbidities m...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XC15
Manufacturer
ROCHE SAS
Presentation

GAZYVARO 1000 mg, solution à diluer pour perfusion (code CIS : 61042996) 1 flacon(s) en verre de 40 ml - Code CIP : 3400958700361

All our publications
    Drug therapy Hematologic cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
Nf8nSrrY7zkUE6Wc